Cantargia AB (OSTO:CANTA) FFO


OSTO:CANTA Cantargia AB OSTO:CANTA
37 GF Score
Price kr2.07
! 2 Warning Signs
View Full Analysis

What is Cantargia AB FFO?

FFO (Funds from operations) only applies to REITs.

OSTO:CANTA
37GF Score
Cantargia AB OSTO:CANTA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB Business Description

Other Exchanges 7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score

Get the complete analysis for OSTO:CANTA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.07
Price